ReviewJournal of neural transmission (Vienna, Austria : 1996)2012
Kynurenines in Parkinson's disease: therapeutic perspectives.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 41 citations in OpenAlex.
- Kynurenine pathway in Parkinson's disease: pathophysiological roles and therapeutic interventions.Inflammopharmacology · 2026Review
- Sex differences in peripheral and central dysregulation of the kynurenine pathway in Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Kynurenine Pathway Dysregulation in Parkinson's Disease: Insights for Disease Modulation and Therapy.International journal of tryptophan research : IJTR · 2025Review
- Review
- Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway.Biomedicines · 2021Review
- The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.International journal of molecular sciences · 2021Review
- Kynurenine pathway in Parkinson's disease-An update.eNeurologicalSci · 2020Review
- Neuroprotection in Parkinson's disease: facts and hopes.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis.International journal of molecular sciences · 2017Review
- Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.Drug design, development and therapy · 2017Review
- The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing.Parkinson's disease · 2015Article
- Model of tryptophan metabolism, readily scalable using tissue-specific gene expression data.The Journal of biological chemistry · 2013Article
- Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder the pathomechanism of which is not yet fully known. With regard to the molecular mechanism of development of the disease, oxidative stress/mitochondrial impairment, glutamate excitotoxicity and neuroinflammation are certainly involved. Alterations in the kynurenine pathway, the main pathway of the tryptophan metabolism, can contribute to the complex pathomechanism. There are several possibilities for therapeutic intervention involving targeting of this altered metabolic route. The development of synthetic molecules that would shift the altered balance towards the achievement of neuroprotective effects would be of great promise for future clinical studies on PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.